

ForPatients

by Roche

Breast Cancer Locally Advanced Breast Cancer Metastatic Breast Cancer HER2-Positive Breast Cancer

A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02595762 ML28801

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (MBC).

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT02595762 ML28801
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
